The U.S. MRI guided neurosurgical ablation market size is likely to be valued at US$65.7 million in 2026 and is expected to reach US$97.5 million by 2033, growing at a CAGR of 5.8% during the forecast period from 2026 to 2033, driven by the growing burden of neurological disorders and increasing adoption of minimally invasive brain procedures. According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 3.0 million adults in the United States were living with active epilepsy during 2021–2022, a major condition treated using MRI-guided laser ablation therapies. In 2024, the CDC reported that active epilepsy affected around 1.2% of the U.S. adult population, underscoring the growing demand for advanced neurosurgical treatment approaches. This demand is further supported by ongoing advancements in MRI-guided laser and focused ultrasound technologies, along with a rising preference for minimally invasive, precision-targeted interventions.

Driver - Rising Incidence of Cancer and Demand for Supportive Care

Modern platforms integrate high-resolution magnetic resonance imaging with advanced thermal monitoring capabilities, enabling neurosurgeons to visualize targeted tissue and treatment effects in real time. MRI-guided laser interstitial thermal therapy and focused ultrasound technologies have improved procedural precision while minimizing damage to surrounding healthy brain structures.

Enhanced treatment planning software, automated temperature mapping, and navigation tools have increased physician confidence and expanded the use of minimally invasive neurosurgical procedures. These innovations continue to improve safety, accuracy, and overall clinical outcomes. Continuous investments in research and development have accelerated the commercialization of next-generation MRI-guided ablation technologies.

Manufacturers are introducing systems with improved imaging quality, faster workflow integration, and enhanced compatibility with existing hospital MRI infrastructure. Real-time MRI thermometry allows physicians to monitor tissue response during treatment, reducing procedural risks and improving effectiveness. These advancements have expanded clinical applications beyond brain tumors to include epilepsy, radiation necrosis, and movement disorders.

Restraint - Shortage of Skilled Neurosurgeons and Specialized Training

The shortage of skilled neurosurgeons trained in MRI-guided ablation procedures represents a significant restraint for the U.S. MRI-guided neurosurgical ablation market. These treatments require expertise in neurosurgery, advanced MRI interpretation, thermal monitoring, and specialized treatment planning. The complexity of integrating imaging technologies with surgical decision-making creates a steep learning curve for healthcare professionals.

Many hospitals and healthcare facilities face challenges in recruiting and retaining personnel with the necessary technical capabilities. Adoption rates are slower in certain regions, limiting patient access to advanced MRI guided therapies despite increasing demand for minimally invasive neurological treatments. Training requirements and procedural complexity also increase operational challenges for healthcare providers seeking to implement MRI-guided ablation programs.

Physicians must undergo extensive education and hands-on experience to effectively use sophisticated laser ablation and focused ultrasound systems. Establishing multidisciplinary teams capable of managing patient selection, imaging guidance, and post-procedural care requires significant institutional commitment. Smaller healthcare facilities struggle to justify these investments due to limited patient volumes and resource constraints.

Opportunity - Expansion into Ambulatory Surgical Centers (ASCs) and Outpatient Settings

Advances in minimally invasive technologies have reduced procedure times, hospital stays, and post-treatment recovery periods, making select neurosurgical interventions increasingly suitable for outpatient care. Patients benefit from reduced hospitalization, faster recovery, and lower overall treatment costs. Healthcare providers are also seeking efficient care delivery models that improve resource utilization while maintaining high clinical standards.

These factors are encouraging the gradual adoption of MRI-guided ablation procedures beyond traditional inpatient hospital environments and specialized neurological centers. Growing healthcare emphasis on value-based care and cost containment is accelerating the transition toward outpatient neurosurgical services.

Ambulatory surgical centers offer operational efficiencies, lower facility expenses, and streamlined patient management compared with conventional hospital settings. As MRI-guided ablation technologies become more user-friendly and procedural protocols continue to evolve, a larger number of eligible patients may be treated in outpatient environments. This shift could expand market reach, increase procedural volumes, and improve accessibility to advanced neurological treatments.

Product Type Insights

MRI guided laser ablation systems are expected to lead the U.S MRI guided neurosurgical ablation market, accounting for approximately 50% of revenue in 2026, driven by extensive clinical adoption in the treatment of brain tumors and drug-resistant epilepsy, where precision and real-time monitoring are critical. These systems enable neurosurgeons to target diseased tissue while minimizing damage to surrounding healthy brain structures. For example, the NeuroBlate System by Monteris Medical, which is widely used in MRI-guided laser interstitial thermal therapy procedures for neurological disorders.

MRI guided focused ultrasound systems are likely to represent the fastest-growing segment in 2026, supported by increasing demand for completely non-invasive treatment options. Unlike conventional surgical approaches, focused ultrasound procedures do not require incisions, resulting in reduced recovery times and lower procedural risks. Favorable patient outcomes and increasing awareness of incisionless therapies are also contributing to rapid market expansion. A notable example includes the Exablate Neuro platform developed by Insightec, which uses MRI guidance and focused ultrasound energy to target specific brain regions without open surgery.

Indication Type Insights

Brain tumors are projected to lead the market, capturing around 45% of the revenue share in 2026, supported by the need for highly precise treatment approaches capable of targeting difficult-to-access tumors while preserving surrounding healthy tissue. MRI-guided ablation procedures provide real-time visualization and temperature monitoring, enabling accurate destruction of tumor tissue with minimal invasiveness. MRI-guided technologies are particularly valuable for patients who may not be suitable candidates for conventional open brain surgery. A prominent example includes the use of the NeuroBlate System in the treatment of recurrent and deep-seated brain tumors, where precise thermal ablation can improve treatment outcomes.

Epilepsy is likely to be the fastest-growing indication in 2026, driven by increasing demand for minimally invasive treatment options for patients with drug-resistant epilepsy. Many patients continue to experience seizures despite medication, creating a need for alternative therapeutic approaches that offer effective seizure control with lower procedural risks. Improvements in imaging accuracy and patient selection have expanded the use of these procedures across specialized epilepsy centers. Growing clinical evidence supporting favorable outcomes has also accelerated physician adoption. For instance, the application of Laser Interstitial Thermal Therapy (LITT) for mesial temporal lobe epilepsy, where MRI-guided laser ablation provides a less invasive alternative to traditional surgical resection.

End-user Insights

Hospitals are expected to dominate the U.S. MRI-guided neurosurgical ablation market, accounting for approximately 50% of the total revenue in 2026. Their leading position is supported by access to advanced MRI infrastructure, specialized neurosurgical expertise, intensive care facilities, and multidisciplinary clinical teams required for complex neurological interventions. Hospitals serve as the primary treatment settings for conditions such as brain tumors, epilepsy, radiation necrosis, and movement disorders, where MRI-guided ablation technologies are increasingly utilized. In addition, large academic medical centers play a key role in driving adoption through clinical research, physician training, and early implementation of innovative treatment technologies. For example, the Mayo Clinic offers advanced MRI-guided neurosurgical procedures through its specialized neuroscience programs.

Ambulatory surgical centers (ASCs) are likely to represent the fastest-growing segment, driven by the increasing shift toward outpatient and minimally invasive care models. Technological improvements have enabled selected neurosurgical procedures to be performed with shorter recovery periods and reduced hospital stays, making outpatient treatment increasingly feasible. As MRI-guided therapies become more efficient and less invasive, the suitability of these procedures for outpatient settings continues to expand. For example, the growing adoption of MRI-guided laser ablation procedures in specialized outpatient neurosurgical centers, where patients can receive advanced treatment with reduced disruption to daily life.

The U.S. MRI guided neurosurgical ablation market exhibits a moderately fragmented structure, driven by continuous technological innovation, increasing clinical adoption of minimally invasive neurosurgical procedures, and growing demand for precision-guided treatment solutions. The market is characterized by the presence of established medical technology companies alongside specialized neurosurgical device developers focused on MRI-guided laser ablation and focused ultrasound platforms. Advancements in real-time MRI thermometry, image-guided navigation, treatment planning software, and non-invasive therapeutic technologies are reshaping the competitive environment.

With key leaders, including Medtronic plc, Monteris Medical, Insightec, Philips Healthcare, GE Healthcare, Siemens Healthineers, Profound Medical, ClearPoint Neuro, Inc., Elekta AB, and Boston Scientific Corporation, the market remains highly innovation-focused. These players compete through product development, MRI integration capabilities, software enhancements, regulatory approvals, strategic partnerships, physician training initiatives, and expansion of clinical indications. Companies are also investing in advanced laser ablation systems, focused ultrasound technologies, and workflow optimization solutions to improve treatment precision, expand patient eligibility, and strengthen their competitive position within the evolving U.S. neurosurgical care landscape.

Key Industry Developments:

• In February 2025, ClearPoint Neuro, Inc. received FDA 510(k) clearance for ClearPoint Navigation Software Version 3.0, expanding precision-guided neurosurgical procedures through enhanced MRI and intraoperative CT-based navigation workflows.
• In October 2025, Monteris Medical and Symphony Robotics announced a strategic collaboration to develop an AI-driven micro-robotic platform for MRI-guided brain laser ablation, combining advanced robotics, artificial intelligence, and laser interstitial thermal therapy (LITT) to enhance precision in the treatment of complex brain tumors, epilepsy, and other neurological disorders.